Clinical Trial

Phase

Target

Study Group

Control Group

Stage

Primary Outcome

S1914/NRG

III

480

Atezolizumab + SBRT

SBRT

I-IIA and limited T3

OS

NRG-LU004

(ARCHON-1)

I

24

Accelerated/Conventional

RT + Durvalumab

none

II-III

Safety

NCT03833154

(PACIFIC-4)

III

733

Durvalumab + SBRT

SBRT/Placebo

II-III

PFS

NCT03924869

III

530

Pembrolizumab + SBRT

SBRT/Placebo

I-II

EFS/OS

NCT03383302

I/II

31

Nivolumab + SBRT

SBRT/Placebo

I-II

Safety

NCT03217071

I-II

12

Pembrolizumab + SBRT

(single dose)-surgery

Pembrolizumab-surgery

I-IIIA

change in tumor infiltrating

CD3 + T cells

NCT03237377

II

9

Durvalumab + tremelimumab/RT

Durvalumab/RT

IIIA

Safety